Axogen CEO Axed 25,000 Shares From His Direct Holdings

Michael D. Dale, Chief Executive Officer of Axogen (NASDAQ:AXGN), executed an open-market merchantability of 25,000 straight held shares connected Dec. 10, 2025, with a reported transaction worth of $750,000 according to the SEC Form 4 filing.

Transaction and post-transaction worth based connected SEC Form 4 reported terms ($30.00).

• How does the size of this transaction comparison to Michael D. Dale’s caller selling activity?
  The 25,000-share merchantability is smaller than the disposition of 61,463 shares the time before, and beneath the caller median insider merchantability size of 43,231 shares.

• Were determination immoderate indirect holdings oregon options exercised arsenic portion of this transaction?
  No indirect holdings, enactment exercises, oregon derivative-related stock movements were disclosed; each shares sold were held straight and transacted successful the unfastened market.

• Axogen is simply a healthcare institution specializing successful surgical solutions for peripheral nervus injuries, leveraging biologic and aesculapian instrumentality technologies. The company’s portfolio focuses connected nervus repair and protection.

• It develops and markets biologically progressive nervus grafts, nervus connectors, nervus protectors, nervus caps, and brushed insubstantial membranes for the surgical repair and extortion of peripheral nerves.

• The institution serves integrative reconstructive, orthopedic, hand, oral,  and maxillofacial surgeons, arsenic good arsenic subject and planetary healthcare providers.

Along with Dale, determination was a beardown magnitude of insider enactment from different executives aboriginal connected successful December. But portion it's not definite wherefore determination were different insider income to adjacent 2025, it's definite that the company's banal performed good that year. AXGN climbed 97.60% successful 2025, having 7 consecutive months of terms gains.

One of Axogen's biggest achievements was connected Dec. 3, 2025, erstwhile the FDA approved its unsocial nervus graft, a quality tissue-based merchandise designed to repair damaged peripheral nerves without requiring nervus insubstantial from the patients themselves. The healthcare institution is expected to person 12 years of marketplace exclusivity of the product, which volition marque it substantially basal retired from competitors.